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ABSTRACT
Background: Liquid biopsy has evolved from being a promising line to becoming 
a validated approach for biomarker testing. However, its utility for individualization of 
therapy has been scarcely reported. In this study, we show how monitoring levels of 
EGFR mutation in plasma can be useful for the individualization of treatment.
Results: Longitudinal EGFR mutation levels in plasma always correlated with 
tumor response ascertained by RECIST criteria. Moreover, decreasing EGFR mutation 
levels were detected in all patients benefiting from locoregional radiotherapy, whereas 
the opposite occurred when a patient progressed soon after radiotherapy treatment. 
Similarly, increasing EGFR mutation levels anticipated disease progression after TKI 
dose reduction, discontinuation of treatment, or reduced bioavailability due to drug 
interactions. In addition, EGFR mutation levels were useful to monitor treatment 
outcome of new therapies and constituted a decisive factor when the clinical situation 
of the patient did not correlate with responses ascertained by radiologist. Finally, our 
results indicate that cancer associated body fluids (pleural, pericardial or cerebrospinal 
fluid) are certainly a suitable source for biomarker testing that can extend EGFR mutation 
detection to biofluids other than blood.
Materials and Methods: A total of 180 serial plasma samples from 18 non-small-
cell lung cancer patients who carried an activating EGFR mutation were investigated 
by digital PCR. 
Conclusions: Monitoring levels of EGFR mutation in plasma allows resolving doubts 
that frequently arise in daily clinical practice and constitutes a major step towards 
achieving personalized medicine.
INTRODUCTION
Tyrosine kinase inhibitors (TKIs) targeting 
the epidermal growth factor receptor (EGFR) have 
substantially improved the quality of life and survival of 
advanced non-small-cell lung cancer (NSCLC) patients 
[1–5]. However, in daily clinical practice, many questions 
concerning the management of patients undergoing TKI 
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therapies remain unanswered. For example, conventional 
monitoring of TKI-treated patients relies on morphologic 
tumor changes, which are generally assessed by computed 
tomography (CT) scans and response evaluation criteria 
in solid tumors (RECIST). However, several studies 
have indicated that RECIST assessment may have some 
limitations when measuring tumor response to TKIs 
[6–8]. Oncologists usually continue to treat NSCLC 
patients harbouring sensitizing EGFR mutation with TKIs 
for extended periods after RECIST progression [9–11] 
although this may be continuing ineffective treatments. 
Indeed, it has been reported that the p.T790M resistance 
mutation can be effectively detected in plasma of advanced 
lung cancer patients several months prior to clinical 
progression [12, 13]. In the same way, dose readjustment 
due to toxicity is performed empirically and whether drug 
efficacy is compromised by dose reduction is difficult to 
measure in daily clinical practice. 
This study assessed dynamic changes in EGFR 
mutation quantification using digital PCR (dPCR) 
methodology in longitudinally collected plasma samples 
from NSCLC patients with activating EGFR mutations. 
We evaluated the clinical information that EGFR mutation 
levels in plasma samples can provide in the context of 
daily clinical practice, not only in terms of tumor response, 
but also with respect to pharmacokinetics and drug 
interactions and individualization of treatment.
RESULTS
Study cohort
This study reports daily clinical practice data 
obtained from 18 NSCLC patients. Routine follow-up 
examinations were performed by a medical oncologist 
every 3 weeks for the first 3 months, and every 12 weeks 
thereafter or as required according to the oncologist’s 
criteria. The pathological characteristics of the study 
population are summarized in Table 1. 
An average of 10 cfDNA samples were analysed 
per patient. cfDNA from all blood samples was analysed 
for the amount of sensitizing EGFR mutation. The 
p.T790M mutation was concomitantly analysed in all 
cfDNA samples. ctDNA fluctuations measured as mutated 
copies/ml or as the ratio mutant allele fraction showed 
similar patterns. According to our data, in positive case 
samples the ratio of mutant DNA molecules vs total DNA 
molecules ranged from 0.10% to 18.5% and the number 
of mutated copies in positive samples ranged from 144 to 
328570 copies/ml.
EGFR mutation levels to monitor non-standard 
therapies
Overall, changes in EGFR mutation levels 
correlated with treatment responses observed in radiology 
assessments. Our results consistently showed that the 
detection of the p.T790M resistant mutation in blood, as 
well as an increment in the quantification of the original 
sensitizing EGFR mutation in serial plasma samples 
correlated with the assessment of progressive disease 
(PD) whereas the opposite occurred in responding patients 
(Supplementary Figure 1). Importantly, a substantial 
decrease of p.T790M and the sensitizing mutation levels 
were notice in a patient (03LSM) treated with cetuximab 
plus afatinib, who maintained in stable disease (according 
to radiological assessments) 493 days after the initiation of 
treatment, suggesting that EGFR mutation levels in plasma 
might be useful to monitor non-standardized treatments 
(Supplementary Figure 1). Of note, a total of 19 samples 
were obtained and analysed from patient 03LSM, which 
implied obtaining an average of one sample every 26 days 
during the 493 days of follow up of this patient. This close 
disease monitoring would be unthinkable if performing 
exclusively imaging tests. 
EGFR mutation levels tracking as a tool to 
monitor dose reduction and drug interactions
Dose adjustments were required in 5 patients 
(04BAA, 07AB, 18MACC, 13CGG and 39YPG). In 
four of them (04BAA, 07AB, 07MACC and 13CGG), 
increased EGFR mutation  levels were detected after TKI 
dose readjustment (Figures 1 and 2), and correlated with 
a subsequent diagnosis of PD. In contrast, no sensitizing 
mutation increase was observed in the remaining patient 
(39YPG) after TKI dose reduction and the patient 
remained in partial response (PR) (Figure 1). In addition, 
in three cases (04BAA, 07AB and 07MACC) a drop 
in EGFR mutation  levels were observed following the 
reintroduction of TKI at full dose.
Finally, one case (12MAPE) corresponded to a 
patient receiving erlotinib who was concomitantly taking 
omeprazole without medical indication, and increasing 
levels of EGFR mutation were detected during co-
administration of both drugs. As shown in Figure 1, 
a reduction to undetectable levels in EGFR mutation 
levels were demonstrated immediately after omeprazole 
withdrawal although these levels increased again soon after.
EGFR mutation levels for monitoring 
oligometastatic disease treatment
During the study, eight patients (02RGB, 07AB, 
17VVM, 05JBP, 18MACC, 19MLCG, 30MMP and 
32LICV) received loco-regional radiotherapy (RT). 
As shown in Supplementary Figure 1, changes in 
EGFR mutation levels were observed during RT, which 
correlated with responses ascertained by the radiologist. 
Importantly, EGFR mutation levels in plasma dropped 
after RT in all patients (Table 2) except for one case 
(18MACC) who progressed after 64 days. The short time 
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to progression in the latter case suggests a systemic rather 
than oligometastatic disease. This could potentially be 
suspected from the increasing EGFR mutation levels in 
plasma after RT. Note that in patient 07AB, RT was given 
with palliative intent, due to the patient´s diagnosis of 
leptomeningeal carcinomatosis.
EGFR mutation levels in patients with doubtful 
diagnoses
Discrepancies with the imaging studies helped 
to resolve a doubtful diagnosis in patient 07AB, in 
which an 18FDG-PET/CT scan failed to detect tumor 
Table 1: Clinico-pathological characteristics of the study population
Median age at diagnosis 59 years (40–73) N %
Sex Women 8 44%
 Men 10 55%
Smoking status Former/quit 10 55%
 Never 8 44%
Histology Adenocarcinoma 18 100%
UICC Stage III 1 5%
 IV 17 94%
EGFR mutation exon 19 deletion 12 67%
 exon 20 insertion 1 5%
 L858R 5 28%
Number of treatment lines  monitored 1 line 3 17%
throughout the study 2 lines 10 55%
 3 lines 5 28%
Figure 1: ctDNA levels (copies/ml) of patients 13CGG, 29YPG, 18MACC and 12MAPE. Therapies are denoted by different 
colored shading. Disease status as ascertained on a CT-scan at different time points is marked with arrows. In cases 13CGG and 18MACC 
an increase in ctDNA is observed after TKI dose reduction correlating with subsequent tumor progression. Increasing levels on ctDNA in 
case 12MAPE suggest a possible interaction between erlotinib and omeprazole. (Abbreviations: SD = stable disease, PR = partial response, 
PD = progressive disease, GF = gefitinib, AFA = afatinib, PMT = Pemetrexed, E = erlotinib, RT = radiotherapy).
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progression in the brain after second-line treatment 
with full-dose gefitinib. However, a head MRI 
confirmed multiple brain metastases which correlated 
with increased plasma levels of EGFR mutation levels 
within the same time frame (Figure 2A). Similarly, 
in patient 11MCMS, 18FDG-PET/CT assessments 
showed a decrease in size and metabolic activity of the 
pulmonary nodule that coincided with EGFR mutation 
quantification. Nevertheless, axillary, inguinal and 
retroperitoneal lymphadenopathies increased in size 
and number, and progressive disease was diagnosed 
after radiological imaging (Figure 2B). Remarkably, 
pathological evaluation of the inguinal adenopathy 
revealed an absence of malignancy. Notably, this patient 
was diagnosed with Sjogren’s syndrome and essential 
mixed cryoglobulinemia.
Table 2: ctDNA fluctuations in patients undergoing radiotherapy (RT) and time to progression 
after RT (days)
Patient Progression after RT Time to progression (days) ctDNA fluctuation
02RGB no - ↓
07AB yes 98 ↓
17VVM no - ↓
05JBP yes 223 ↓
18MACC yes 64 ↑
19MLCG no - ↓
30MMP no - ↓
32LICV no  ↓
Figure 2: Discrepancies in the assessment of tumor response between ctDNA and TAC. (A) ctDNA levels (copies/ml) of 
patient 07AB. Therapies are denoted by different colored shading. Disease status as ascertained on a CT-scan at different time points is 
marked with arrows. As shown, the 18-FDG PET-CT scan at day 150 failed to detect brain metastases that were however diagnosed by 
MRI. (Abbreviations: PR = partial response, PD = progressive disease, GF = gefitinib, RT = radiotherapy). (B) Mutation tracking profile 
of case 11MCMS and treatment outcome assessed according to RECIST criteria v.1.1. SD = stable disease, PD = progressive disease. 18-
FDG PET-CT scans at time points are marked with a discontinuous line. Images from data points A, B and C are presented. Lung tumor 
and adenopathies are denoted by arrows.
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Body fluids to improve diagnostic yield of ctdna
In four cases, paired samples were collected from 
body fluid and plasma.  Specifically the cytological 
evaluation of the pleural and pericardial effusions 
reveal the presence of lung adenocarcinoma cells in all 
three cases. Similarly, according to pathologist report 
the presence of lung adenocarcinoma metastasis in 
cerebrospinal fluid was confirmed. As shown in Table 3, 
EGFR mutation levels was always higher in the body 
fluids compared to plasma. In one case (24MAG) 
(Supplementary Figure 1) p.T790M mutation was not 
detected in re-biopsy FFPE or in the corresponding 
plasma sample. However, p.T790M mutation was 
detected in the ctDNA isolated from malignant 
pleural effusion at progression and sensitizing levels 
dramatically went down after treatment initiation with 
osimertinib.
DISCUSSION
The majority of previous liquid biopsy studies in 
patients with EGFR mutations have primarily reported 
the feasibility of detecting resistance and sensitizing 
EGFR mutations and how much earlier tumor progression 
can be predicted using liquid biopsy than CT-scans 
[12–16]. However, the usefulness of EGFR mutation 
detection in plasma may not be limited to the early 
detection of progression, as it could also assist clinicians 
in daily clinical practice in terms of dose readjustments 
and drug interactions, among other aspects. For example, 
where there are no differences in the clinical effectiveness 
of different TKIs, in most cases the choice relies either 
on the oncologist’s experience and personal decision, 
or the expected toxicity. In this respect, we know that 
although the frequency of all-cause severe adverse 
effects is somewhat similar among TKIs, they may have 
differing toxicity profiles [17, 18]. Until now, whether 
dose reductions after adverse events could influence 
patient survival was unknown, since these events are 
relatively rare (less than 6%). From our data, it can be 
speculated that EGFR mutation level quantification can, 
at least partially, assist clinicians to lower treatment dose 
minimizing undesired outcomes. As presented, increasing 
EGFR mutation levels anticipated disease progression 
after TKI dose reduction whereas EGFR mutation levels 
dropped when patient maintained response despite dose 
reduction.  Similarly, we report the clinical utility of 
EGFR mutation levels in plasma  to detect drug-drug 
interactions that we know might occur even with some 
common, commercially available, soft drinks [19, 20]. 
As shown in Figure 1, increasing plasma levels of EGFR 
mutation were found in a patient (12MAPE) who was 
concomitantly taking erlotinib and omeprazole, suggesting 
that omeprazole may reduce effectivity of erlotinib upon 
co-administration.
We similarly consider that EGFR mutation levels in 
plasma could help to better redefine the use of determined 
treatment combinations, as occurred with  patient 
03LSM, who was  treated with afatinib plus cetuximab 
after progression to afatinib. The rationale of this 
combination is based on solid preclinical data indicating 
that concomitant administration of the two drugs can 
eventually overcome p.T790M-mediated resistance [21]. 
However, in a phase Ib trial, dual inhibition of EGFR 
with afatinib and cetuximab was modestly active among 
patients with acquired resistance with an objective 
response rate of 29% and median progression free survival 
of 4.7 months (95% confidence interval, 4.3–6.4) [22]. 
Consequently, this combination has not been extended 
to routine clinical practice.  Patient 03LSM exemplifies 
how tumor monitoring through liquid biopsy can open up 
new perspectives for the use of new therapies, anti-EGFR 
re-challenge, or even N-of-1 trials [23].  On one hand, 
liquid biopsy reduces the time for treatment outcome 
monitoring (from 4 weeks when based in imaging tests 
Table 3: ctDNA mutant allele fraction (%) and ctDNA copies/ml in paired samples from plasma 
and body fluids
Patient ctDNA Source
p.T790M mutant allele 
fraction (%) p.T790M copies/ml
Sensitizing mutant 
allele fraction (%) Sensitizing copies/ml
16JLPG Plasma ND ND 0.345 1804.5
 CSF ND ND 6.431 785.25
27FJAR Plasma 0.144 436.812 0.524 676.062
 PE 10.253 334355.500 20.74 510110
24 MAG Plasma ND ND 0.427 409.625
 PE 3.18 62225.17 9.66 23080.38
35MJSS Plasma 0.11 155.56 0.80 1259.87
 PCE 9.66 3360850.33 26.88 9607335.10
Abbreviations: ND = not detected, CSF = cerebrospinal fluid, PE = pleural effusion, PEC pericardial fluid).
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results to 5 days when based in liquid biopsy tests results, 
in our institution). On the other, changes in EGFR 
mutation levels in plasma can be observed within days 
(data not shown). This enables a closer real time follow up, 
getting ahead of the radiological response, and therefore 
improving decision-making regarding treatment selection, 
modification or continuation. 
Finally, our results indicate that cancer associated 
body fluids are certainly a suitable source for biomarker 
testing that can extend EGFR mutation detection to bio-
fluids other than blood (Table 3). As proved with patient 
24MAG, who presented a p.T790M negative biopsy 
both in the solid tumor and blood, but was positive in the 
malignant pleural effusion. Malignant pleural effusions are 
frequently observed in advanced lung adenocarcinomas 
[24] and thoracentesis may be necessary for diagnosis and 
treatment. However, pleural fluid is usually discarded after 
the removal of cell component for cytological examination 
despite being helpful for EGFR mutation detection.
In conclusion, sensitizing and resistance mutation 
quantification in plasma throughout the course of a 
NSCLC cancer allows us to resolve doubts that frequently 
arise in daily clinical practice and reduce time for decision, 
which constitutes a major step towards personalized 
medicine.
MATERIALS AND METHODS
Study population and data management
A total of 18 cases from NSCLC patients were 
included in the study. Written informed consent was 
obtained from every patient. Eligible patients were both 
male and female patients with a pathologically confirmed 
diagnosis of stage IIIB-IV NSCLC tumor with an EGFR 
mutation in primary tumor tissue. A complete staging 
workup was performed prior to recruitment into the study. 
Blood samples were collected as follows: at diagnosis, when 
patients returned for re-evaluation and when appointed by 
a medical oncologist due to uncertainties about a patient’s 
clinical status, radiological assessments, toxicity events or 
TKI dose reduction. Demographic characteristics, clinico-
pathological features, tumor mutation status, vital status, 
disease status, drug dose adjustments or discontinuation of 
medication were collected.
The study was approved by the Hospital Puerta de 
Hierro Ethics Committee (internal code PI/144-14) and 
was conducted in accordance with the precepts of the Code 
of Ethics of The World Medical Association (Declaration 
of Helsinki).
Laboratory procedures
For EGFR mutation levels quantification, peripheral 
whole blood was collected from each subject in a 5 ml EDTA 
tube containing a gel barrier (PPT™, BECTON DICKINSON) 
to separate the plasma from blood cells after centrifugation. 
All samples were processed as previously described 
[14, 25]. cfDNA was extracted using a starting volume of 
1 ml of plasma with a Maxwell® RSC instrument 
(Promega), using the Maxwell® RSC ccfDNA Plasma Kit, 
as specified by the manufacturer and was eluted in 50 µl 
of the supplied buffer. In addition, biological fluids with 
malignant abnormal cytology, including malignant pleural 
(N = 2) and pericardial (N = 1) effusions and cerebrospinal 
fluid (N = 1) were also analysed for EGFR mutation levels. 
Biological fluids were centrifuged and the supernatant 
was used for cfDNA isolation using the same protocol. 
Germline DNA was obtained from blood leukocytes with 
a MagNA Pure LC total nucleic acid extraction kit in a 
MagNA Pure LC instrument (Roche Diagnostics, Penzberg, 
Germany). cfDNA samples were then analysed by dPCR 
using Rare Mutation Assays for p.T790M (AHRSROS), 
p.L858R (AHRSRSV), p.G719A (AHABH29), 
p.G719C (AH0JEWC), p.G719S (AHZAGP4), p.H773_
V774insH (AH5I7PA), p.D770_N771insG (AH7031Q), 
p.L747_T751 > P (AHFA92K), p.L747_A750 > P 
(AHS1PY0), p.E746_T751 > A (AHHS6E0), p.E746_
A750delELREA (AHLJ0XO), p.L747_T751delLREAT 
(AHCTDP3) and p.L747_S752delLREATS (AHGJ78R ) 
on a QuantStudio®3D Digital PCR System (Applied 
Biosystems, South San Francisco, CA), as previously 
described [14]. A wt control DNA was included in every run. 
Tumor response evaluation
Computed tomography (CT) measurements and 
magnetic resonance imaging (MRI) were obtained as 
clinically indicated. The clinical response was evaluated 
according to RECIST criteria v1.1 combined with a 
blinded medical judgment of benefits from the treatment. 
Additionally, whole body 18F-fluoro-2-deoxy-D-glucose-
positron emission tomography (18FDG-PET)- CT scans 
were performed as clinically indicated using a Siemens 
Biograph 6 True Point PET-CT (Siemens). A 350-450MBq 
18F-FDG dose was administered 55-65 min prior to image 
acquisition. Reconstruction was performed using an 
iterative method and attenuation/scatter correction.
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